Brokerages Set Ra Pharmctl Inc (RARX) Target Price at $25.60

Ra Pharmctl Inc (NASDAQ:RARX) has earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.00.

RARX has been the subject of several analyst reports. Zacks Investment Research raised shares of Ra Pharmctl from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Jefferies Group LLC set a $25.00 price target on shares of Ra Pharmctl and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, Royal Bank Of Canada initiated coverage on shares of Ra Pharmctl in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target for the company.

Shares of Ra Pharmctl (NASDAQ:RARX) traded up 8.13% during mid-day trading on Monday, hitting $15.82. 126,776 shares of the company’s stock traded hands. The firm has a 50-day moving average of $14.66 and a 200 day moving average of $14.66. Ra Pharmctl has a 52 week low of $12.05 and a 52 week high of $24.12. The company’s market cap is $357.67 million.

Ra Pharmctl (NASDAQ:RARX) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). Equities research analysts predict that Ra Pharmctl will post ($2.31) EPS for the current year.

WARNING: “Brokerages Set Ra Pharmctl Inc (RARX) Target Price at $25.60” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/14/brokerages-set-ra-pharmctl-inc-rarx-target-price-at-25-60.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company raised its stake in Ra Pharmctl by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after buying an additional 2,543 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in Ra Pharmctl by 97.0% during the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after buying an additional 3,859 shares during the last quarter. California State Teachers Retirement System raised its stake in Ra Pharmctl by 26.1% during the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after buying an additional 4,300 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Ra Pharmctl by 7.0% during the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after buying an additional 4,751 shares during the last quarter. Finally, American International Group Inc. bought a new position in Ra Pharmctl during the first quarter worth $102,000. 66.26% of the stock is owned by institutional investors and hedge funds.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical c

RARX has been the subject of several analyst reports. Zacks Investment Research raised shares of Ra Pharmctl from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Jefferies Group LLC set a $25.00 price target on shares of Ra Pharmctl and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, Royal Bank Of Canada initiated coverage on shares of Ra Pharmctl in a research note on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target for the company.

Shares of Ra Pharmctl (NASDAQ:RARX) traded up 8.13% during mid-day trading on Monday, hitting $15.82. 126,776 shares of the company’s stock traded hands. The firm has a 50-day moving average of $14.66 and a 200 day moving average of $14.66. Ra Pharmctl has a 52 week low of $12.05 and a 52 week high of $24.12. The company’s market cap is $357.67 million.

Ra Pharmctl (NASDAQ:RARX) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). Equities research analysts predict that Ra Pharmctl will post ($2.31) EPS for the current year.

WARNING: “Brokerages Set Ra Pharmctl Inc (RARX) Target Price at $25.60” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/14/brokerages-set-ra-pharmctl-inc-rarx-target-price-at-25-60.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company raised its stake in Ra Pharmctl by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock worth $204,000 after buying an additional 2,543 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in Ra Pharmctl by 97.0% during the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock worth $167,000 after buying an additional 3,859 shares during the last quarter. California State Teachers Retirement System raised its stake in Ra Pharmctl by 26.1% during the second quarter. California State Teachers Retirement System now owns 20,800 shares of the company’s stock worth $390,000 after buying an additional 4,300 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Ra Pharmctl by 7.0% during the second quarter. Goldman Sachs Group Inc. now owns 73,103 shares of the company’s stock worth $1,370,000 after buying an additional 4,751 shares during the last quarter. Finally, American International Group Inc. bought a new position in Ra Pharmctl during the first quarter worth $102,000. 66.26% of the stock is owned by institutional investors and hedge funds.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply